British Land Company (BLND) M&A announcement summary

Deal rationale and strategic fit

• Acquisition targets five well-located assets in the Golden Triangle, including sites in London, Oxford, and Cambridge, strengthening the science and technology platform and expanding the footprint in high-demand innovation clusters.

• Diversifies and enhances the occupier base beyond life sciences to include AI, tech, green, and physical sciences, leveraging platform expertise and complementing the existing ecosystem.

• Capitalizes on accelerating demand in the UK science and technology sectors, with AI and tech investment at record highs, offsetting softness in life sciences.

• Provides Life Science REIT shareholders with diversified exposure to growth subsegments and access to a market-leading operating platform.

• Addresses Life Science REIT's challenges from macroeconomic headwinds, persistent share price discount, and limited ability to raise capital.

Financial terms and conditions

• Offer comprises 14.1p in cash and 0.07 new shares per target share, valuing each at 42.8p and the total equity at £150 million, representing a 21% premium to the prior closing price and a 15% premium to the 3-month VWAP.

• Life Science REIT shareholders will own approximately 2.4% of the enlarged group post-completion.

• GBP 150 million equity value funded 33% cash, 67% shares, with minimal impact on LTV; cash consideration funded from existing resources.

• Acquisition price of GBP 276 million for assets with a GBP 333 million book value; offer at a 26% discount to unaudited EPRA NTA.

• Life Science REIT shareholders receive liquidity and continued sector exposure.

Synergies and expected cost savings

• Significant administrative and finance cost savings expected by integrating assets onto the acquirer's platform and refinancing at lower rates (4.5% vs. 6%).

• Immediate EPS accretion from synergies, with further upside from lease-up of vacant space and capturing embedded reversion.

• Substantial cost synergies from reduced admin expenses and cessation of management agreements.